Skip to content
10-K

Annual Report

Contineum Therapeutics, Inc. CTNM

0001628280-26-015165

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 27.7M sh
Shares Diluted FY 2025 · Dec 31, 2024 19.35M sh
Capex FY 2025 · Dec 31, 2025 $231K
Capex FY 2025 · Dec 31, 2024 $514K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$55.31M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$32.85M
Cash And Equivalents FY 2025 · Dec 31, 2025 $75.6M
Cash And Equivalents FY 2025 · Dec 31, 2024 $21.94M
Stockholders Equity FY 2025 · Dec 31, 2025 $260.99M
Stockholders Equity FY 2025 · Dec 31, 2024 $198.07M
Stockholders Equity FY 2025 · Dec 31, 2023 −$67.94M
Current Liabilities FY 2025 · Dec 31, 2025 $9.74M
Current Liabilities FY 2025 · Dec 31, 2024 $9.97M
Total Liabilities FY 2025 · Dec 31, 2025 $15.65M
Total Liabilities FY 2025 · Dec 31, 2024 $14.78M
Current Assets FY 2025 · Dec 31, 2025 $267.92M
Current Assets FY 2025 · Dec 31, 2024 $206.39M
Total Assets FY 2025 · Dec 31, 2025 $276.64M
Total Assets FY 2025 · Dec 31, 2024 $212.85M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.17
Eps Diluted FY 2025 · Dec 31, 2024 −$2.18
Eps Basic FY 2025 · Dec 31, 2025 −$2.17
Eps Basic FY 2025 · Dec 31, 2024 −$2.18
Sga Expense FY 2025 · Dec 31, 2025 $16.54M
Sga Expense FY 2025 · Dec 31, 2024 $12.47M
Rd Expense FY 2025 · Dec 31, 2025 $51.52M
Rd Expense FY 2025 · Dec 31, 2024 $38.42M
Net Income FY 2025 · Dec 31, 2025 −$59.98M
Net Income FY 2025 · Dec 31, 2024 −$42.26M
Operating Income FY 2025 · Dec 31, 2025 −$68.06M
Operating Income FY 2025 · Dec 31, 2024 −$50.89M